Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New adaptive brain stimulator could save battery life in Parkinson's patients

NCT ID NCT07106242

First seen Apr 02, 2026 · Last updated Jun 20, 2026 · Updated 6 times

Summary

This study tested a new type of deep brain stimulation (DBS) called adaptive DBS (aDBS) in 25 people with Parkinson's disease. The device automatically adjusts stimulation based on brain signals, unlike standard continuous DBS. The main goal was to see if aDBS uses less total electrical energy. Participants tried both modes to compare energy use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-0033, Japan

  • Juntendo University Nerima Hospital

    Tokyo, Nerima-ku, 177-8521, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Adaptive deep brain stimulation (aDBS) device

What this could lead to

If successful, aDBS could make DBS therapy more efficient, potentially reducing battery changes and side effects for people with Parkinson's.

What could go wrong

This is a small, completed study focused on energy use, not symptom improvement. The benefits of aDBS over standard DBS are still uncertain and may not apply to all patients.

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.